Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 33: | Line 33: | ||
*[[Mediastinal gray-zone lymphoma]] | *[[Mediastinal gray-zone lymphoma]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| − | |||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| + | *[[Pheochromocytoma]] | ||
*[[Plasma cell leukemia]] | *[[Plasma cell leukemia]] | ||
*[[Post-transplant lymphoproliferative disorder]] | *[[Post-transplant lymphoproliferative disorder]] | ||
| Line 160: | Line 160: | ||
[[Category:Mediastinal gray-zone lymphoma medications]] | [[Category:Mediastinal gray-zone lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| − | |||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | [[Category:Pheochromocytoma medications]] | ||
[[Category:Plasma cell leukemia medications]] | [[Category:Plasma cell leukemia medications]] | ||
[[Category:Post-transplant lymphoproliferative disorder medications]] | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
Revision as of 01:18, 28 January 2018
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Bone sarcoma
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL/SLL)
- CNS lymphoma
- Acquired coagulopathy
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Osteosarcoma
- Peripheral T-cell lymphoma
- Pheochromocytoma
- Plasma cell leukemia
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Small cell lung cancer
- T-cell acute lymphoblastic leukemia
- Thymoma
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
Also known as
- Code names: Asta B 518, B-518, WR-138719
- Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclokebir | Cicloxal | Clafen | Claphene |
| Cyclam | Cycloblastin | Cycloblastine | CYCLO-cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham |
| Cyclophosphamid | Cyclophosphane | Cyclostin | Cyclostine | Cyclotox | Cycloxan | Cycram | Cydoxan |
| Cyklofosfamid | Cyphos | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana |
| Enduxan | Formitex | Fosfaseron | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina |
| Mitoxan | Neophos | Neosar | Oncomide | Oncophos | Procytox | Revimmune | Sendoxan |
| Siklofos | Syklofosfamid | Tymtran | Zuviphos | Zycram | Zytoxan | ||
References
Categories:
- Drug index
- Intravenous medications
- Oral medications
- Irritant chemotherapy
- Neutral chemotherapy
- Alkylating agents
- Nitrogen mustards
- Immunosuppressants
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Bone sarcoma medications
- Breast cancer medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Acquired coagulopathy medications
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Peripheral T-cell lymphoma medications
- Pheochromocytoma medications
- Plasma cell leukemia medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell acute lymphoblastic leukemia medications
- Thymoma medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1959
- PMDA approved drugs
- WHO Essential Cancer Medicine